TRON is delighted to announce a scientific article published in Oncotarget.
PLAC1 (placenta enriched 1) is a mammalian trophoblast-specific protein, which is aberrantly expressed in various human cancers. AKT activation mediates the downstream effects of PLAC1, which include involvement in tumor cell motility, migration, and invasion. In this article, TRON authors Barea Roldán et al. show, in human choriocarcinoma and breast cancer cell lines, that PLAC1 is both secreted and adheres to the extracellular matrix, where it forms a trimeric complex with fibroblast growth factor 7 (FGF7) and its receptor, FGF receptor 2 IIIb (FGFR2IIIb). They go on to show that PLAC1 signaling via FGFR2IIIb activates AKT phosphorylation. Given the interest in the FGF pathway in anticancer therapeutic strategies, these data promote PLAC1 as a promising drug target for cancer.
You can read the original article here.